The American Cancer Society updated its prostate cancer screening guideline in 2026, and the recommendation is more specific than a headline suggests. It does not say every man should be screened in midlife. It sets when to start, how often to test and when to stop, based on age, race, family history and life expectancy.[1] If you are in midlife, the first thing to find out is which group you belong to.
The short version
The guideline sorts men by risk. These are the ages and intervals it gives.[1]
- Average-risk men (non-Black men with no family history of prostate cancer): screening every two years from age 50 to 69.
- Black men: screening every year from age 45 to 69.
- Non-Black men with a strong family history (multiple first-degree relatives diagnosed with prostate cancer at any age, or one diagnosed before age 65): screening every year from age 45 to 69.
- Non-Black men with one first-degree relative diagnosed at age 65 or older: screening every two years from age 45 to 69.
- Men ages 70 to 74: the balance of benefits and harms is uncertain, and the guideline recommends an individualized decision. For men who choose screening, the guideline says screening should be conducted every two years through age 74, and may be discontinued after any PSA below 3 ng/mL.[1]
- Men with a life expectancy under 10 years: screening is not recommended. Screening should stop at age 75.
These recommendations do not apply to men who have already been diagnosed with prostate cancer. Men with a known or suspected hereditary cancer syndrome, such as a BRCA2 gene mutation, are a higher-risk group with their own recommendations for risk assessment, genetic counseling and management. The guideline says they should talk with their health care provider about when to start screening.[1]
Why “everyone” is the wrong takeaway
The guideline does not say every man in midlife should be tested. Average-risk screening starts at 50. The guideline also names men for whom screening is not recommended, or should stop. Your clinician is the person who can turn these categories into a plan for you.
What the guideline says about benefits and harms
The guideline states that “accumulating evidence shows that prostate-specific antigen (PSA)-based screening significantly reduces prostate cancer mortality and advanced-stage diagnosis.”[1] It also concludes that the benefits of screening outweigh the harms.[1] Several of the authors are ACS staff. The guideline states that “ACS staff did not formulate recommendations or vote on approval of the final guideline.”[1] The benefit conclusion rests on the ACS’s own systematic review and modeling study, so it is not an independent check.[1]
The guideline notes that the trial evidence has not been uniform. The ERSPC trial in Europe reported a prostate cancer mortality reduction with PSA-based screening. The PLCO trial in the United States reported no prostate cancer mortality reduction. The guideline says the negative PLCO results have been largely dismissed, because about 90% of men in its control arm had at least one PSA test. It also cites a modeling study that suggested the ERSPC and PLCO screening arms would show comparable mortality reductions, and a third trial, CAP, that reported a small reduction after a one-time PSA test.[1]
If PSA is 3.0 ng/mL or higher at age 69 or younger, or 6.5 ng/mL or higher at ages 70 to 74, the guideline says the man should be retested first, preferably 2 weeks to 3 months after the first test, before further evaluation is considered.[1] For most men whose elevated PSA is confirmed on repeat testing, the guideline says they should be offered MRI and/or a validated biomarker test to guide biopsy decisions.[1]
Before screening starts, the guideline asks clinicians to make sure patients are informed about “the benefits, limitations, and harms of screening; the potential follow-up evaluations of elevated PSA levels; and the expectation that low-risk cancers will initially be managed with active surveillance.”[1] In plain terms, a raised PSA leads to more tests. Low-risk cancers are watched over time rather than treated right away. The guideline does give some trial rates. In the PLCO trial, 10% of men who completed at least one PSA test in the first four rounds had at least one false-positive result. Across five ERSPC centers, 18% of men attending one or more rounds had at least one false-positive result.[1]
The guideline names these harms of screening: false-positive results, biopsy-related complications, overdiagnosis, overtreatment, and treatment complications, such as long-term urinary, sexual and bowel dysfunction.[1] Overdiagnosis means finding slow-growing cancers that would never have caused symptoms, which can lead to treatment that was not needed.
What the guideline does not settle
- It is a screening guideline, not a treatment guideline. It does not show that screening lowers the risk of death for every man.[1]
- The recommendations do not cover men already diagnosed with prostate cancer, or men with a hereditary cancer syndrome (see the note above). Readers who need the full evidence should read the guideline itself.[1]
- A companion evidence map in the journal Cancer reviewed 68 studies of biomarker-based pathways in prostate cancer screening. Across those studies, biomarker-based pathways were generally reported to reduce biopsies while maintaining detection of clinically significant cancer. Its authors wrote: “However, heterogeneity in study populations and evaluated pathways limits interpretation.” It is supporting context, not the guideline itself.[2]
Questions to take to your clinician
A screening decision depends on details that a general guideline cannot see. Bring these questions to a clinician who knows your history.
- Which group do I fall into? Include my age, race, and family history, including how many first-degree relatives had prostate cancer and at what ages.
- Given my overall health, what is a realistic life expectancy for me, and does screening still make sense?
- If my PSA is elevated, what would the follow-up look like, including MRI or other tests?
- If a low-risk cancer were found, what would active surveillance involve for me?
Whether to be tested, how often, and what to do with the results are decisions for you and your clinician. This post does not tell you whether to get screened.
References
[1] Hoffman RM, Wolf AMD, Etzioni R, et al. American Cancer Society guideline for the early detection of prostate cancer, 2026. CA: A Cancer Journal for Clinicians. 2026;76(6). DOI: 10.3322/caac.70112. Finding as used: risk-stratified screening. Every two years from 50 to 69 for average-risk men. Every year from 45 to 69 for Black men and for non-Black men with a strong family history. Every two years from 45 to 69 for non-Black men with one first-degree relative diagnosed at 65 or older. Individualized decisions at 70 to 74; for men who choose screening, every two years through 74 and possible discontinuation after any PSA below 3 ng/mL. Not recommended with life expectancy under 10 years; discontinue at 75. The recommendations do not apply to individuals previously diagnosed with prostate cancer; men with a known or suspected hereditary cancer syndrome such as BRCA2 gene mutations are a higher-risk subgroup referred to specialty guidance and genetic counseling. Men with an inherited genetic condition associated with prostate cancer should discuss with their health care provider about when to start screening (Table 2). Men with an abnormal PSA (3 ng/mL or higher at ages 69 and younger; 6.5 ng/mL or higher at ages 70 to 74) should be retested, preferably 2 weeks to 3 months later, before further evaluation. Most men with elevated PSA confirmed on repeat testing should be offered MRI and/or a validated biomarker test to guide biopsy decisions. Named harms: false-positive results, biopsy-related complications, overdiagnosis, overtreatment, and treatment complications. PLCO 10% and ERSPC 18% false-positive rates, as reported in the guideline’s Rationale section. ACS staff did not formulate recommendations or vote on approval; the benefit conclusion comes from the ACS systematic review and modeling study. ↑︎ a b c d e f g h i j k l m n o p
[2] Shiau RL, Griffin JC, Troutman CAB, Relevo R, Kondo KK. Biomarker use in the prostate cancer screening pathway: Maps of the evidence. Cancer. 2026;132(22):e70627. DOI: 10.1002/cncr.70627. Finding as used: evidence map of 68 studies. Across 68 studies, biomarker-based pathways were generally reported to reduce biopsies while maintaining clinically significant prostate cancer (csPCa) detection compared to nonbiomarker pathways. Verbatim: “However, heterogeneity in study populations and evaluated pathways limits interpretation.” Companion context only, not the ACS guideline. ↑︎

Kurt Greiner
Kurt is a digital strategist and IT professional blending emerging technology with practical application, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.

Leave a Reply